Sunshine Guojian Pharmaceutical (shanghai) Co., Ltd.

Sunshine Guojian Pharmaceutical (shanghai) Co., Lt

Haomin Huang

Zhenping Zhu

Jie Zhao

Le Zhao

Liangfeng Jiang

Jianhe Chen

Lei Huang

Fei Xu

Chenghai Zhang

Xuesai Zhang

Qingrou Li

Jinlin Guo

Wei Dang

Lingqiao Zhu

Honghai Gao

Jianguo Xiao

Huiling Wu

Changling Gu

Mengying Xia

Yuping Huang

Provided are an anti-HER2/PD1 bispecific antibody, preparation method, and antitumor application. Specifically, a single-chain variable fragment scFv and an immunoglobulin antibody IgG are connected by means of a peptide linker to obtain a bispecific antibody; the bispecific antibody can simultaneously target the tumor cell surface molecule HER2 antigen and T lymphocyte surface molecule PD-1. The results of experimentation show that the bispecific antibody provided is capable of inhibiting the proliferation of HER2-positive tumor cells while also blockading the binding of PD-1/PD-L1, releasing the suppressive state of T cells and performing an antitumor function.

Anti-HER2/PD1 bispecific antibody

Provided is a method for preparing a recombinant human nerve growth factor, which can be used as a therapeutic drug.

Method for preparing recombinant human nerve growth factor

Provided is an antibody binding to human HER2 or an antigen-binding fragment thereof capable of specifically binding to human HER2. Compared with Perjeta, the combination of the antibody or an antigen-binding fragment thereof and Herceptin has improved biological activity in inhibiting the proliferation of tumor cells overexpressing HER2. The antibody or an antigen-binding fragment thereof has an antigen-binding epitope different from known antibodies binding to human HER2, can be used to prepare a drug for treating a disease related to HER2 overexpression, such as cancer, and has good prospects for clinical application.

Antibody binding to human HER2 and preparation method and use thereof

Provided are an antibody that binds to human PD-L1, and a tetravalent bispecific antibody against PD-1 and PD-L1 constructed based on the antibody that binds to human PD-L1. The tetravalent bispecific antibody requires no Fc modification, has no mismatch problems, and the preparation method thereof is simple. The biological activities and physical and chemical properties of the tetravalent bispecific antibody are similar with or even better than those of the monoclonal antibodies.

Tetravalent bispecific antibody against PD-1 and PD-L1

Disclosed are antibodies binding to human IL-4R, having identical variable regions and different constant regions, wherein the variable regions can specifically bind to human IL-4R, and the constant regions affect the activity of the whole antibody through an amino acid site mutation. The above-mentioned antibodies can be used to treat diseases related to IL-4R overexpression, such as atopic dermatitis, asthma, etc., and thus possesses good clinical application prospects.

Antibodies binding to human IL-4R, preparation method therefor and use thereof

Disclosed is a monoclonal antibody that binds to human IL-5. The monoclonal antibody that binds to human IL-5 has a good biological activity for inhibiting TF-1 cell proliferation induced by IL-5 and blocking the interaction between IL-5 and IL-5RA, has a different antigen epitope from the known anti-human IL-5 antibody, can be used for preparing drugs for treating diseases mediated by the over-expression of eosinophilic granulocytes (such as asthma), and has a good clinical application prospect.

Monoclonal antibody binding to human IL-5, preparation method therefor and use thereof

An anti-human PD-1 monoclonal antibody, and a preparation method therefor and an application thereof. The anti-human PD-1 monoclonal antibody has good bioactivity, can effectively bind with an extracellular region of a human PD-1 protein receptor, and can effectively seal PD-1 protein at protein level and cellular level and block the binding of the PD-1 protein with a ligand PD-L1, thereby effectively enhancing immunity. The monoclonal antibody can be applied independently or jointly with other antitumor drugs to tumor immunotherapy and the diagnosis and screening of patients with PD-L1 positive tumors; and the monoclonal antibody has a promising prospect in the preparation of drugs for treating tumors, resisting autoimmune diseases and the like.

Anti-PD-1 monoclonal antibody, and preparation method therefor and application thereof

Growing community of inventors

Shanghai, China

Haomin Huang